Advertisement

Mesalamine Did Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials

      Background & Aims

      No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. We investigated the efficacy of mesalamine in preventing recurrence of diverticulitis in 2 identical but separate phase 3, randomized, double-blind, placebo-controlled, multicenter trials (identical confirmatory trials were conducted for regulatory reasons).

      Methods

      We evaluated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent diverticulitis in 590 (PREVENT1) and 592 (PREVENT2) adult patients with ≥1 episodes of acute diverticulitis in the previous 24 months that resolved without surgery. Patients received mesalamine (1.2 g, 2.4 g, or 4.8 g) or placebo once daily for 104 weeks. The primary end point was the proportion of recurrence-free patients at week 104. Diverticulitis recurrence was defined as surgical intervention at any time for diverticular disease or presence of computed tomography scan results demonstrating bowel wall thickening (>5 mm) and/or fat stranding consistent with diverticulitis. For a portion of the study, recurrence also required the presence of abdominal pain and an increase in white blood cells.

      Results

      Mesalamine did not reduce the rate of diverticulitis recurrence at week 104. Among patients in PREVENT1, 53%−63% did not have disease recurrence, compared with 65% of those given placebo. Among patients in PREVENT2, 59%−69% of patients did not have disease recurrence, compared with 68% of those given placebo. Mesalamine did not reduce time to recurrence, and the proportions of patients requiring surgery were comparable among treatment groups. No new adverse events were identified with mesalamine administration.

      Conclusions

      Mesalamine was not superior to placebo in preventing recurrent diverticulitis. Mesalamine is not recommended for this indication. ClinicalTrials.gov ID: NCT00545740 and NCT00545103.

      Keywords

      Abbreviations used in this paper:

      AE (adverse event), CT (computed tomography), HRQOL (health-related quality of life), HUI2 (Health Utilities Index Version Mark 2), QD (once daily), TEAE (treatment-emergent adverse event)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stollman N.
        • Raskin J.B.
        Diverticular disease of the colon.
        Lancet. 2004; 363: 631-639
        • Parks T.G.
        Natural history of diverticular disease of the colon.
        Clin Gastroenterol. 1975; 4: 53-69
        • Shahedi K.
        • Fuller G.
        • Bolus R.
        • et al.
        Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy.
        Clin Gastroenterol Hepatol. 2013; 11: 1609-1613
        • Stollman N.H.
        • Raskin J.B.
        Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology.
        Am J Gastroenterol. 1999; 94: 3110-3121
      1. Murphy T, Hunt RH, Fried M, et al. Diverticular disease. 2007. Available: http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/07_diverticular_disease.pdf. Accessed January 17, 2014.

        • Eglinton T.
        • Nguyen T.
        • Raniga S.
        • et al.
        Patterns of recurrence in patients with acute diverticulitis.
        Br J Surg. 2010; 97: 952-957
        • Rafferty J.
        • Shellito P.
        • Hyman N.H.
        • et al.
        Practice parameters for sigmoid diverticulitis.
        Dis Colon Rectum. 2006; 49: 939-944
        • Ford A.C.
        • Achkar J.P.
        • Khan K.J.
        • et al.
        Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.
        Am J Gastroenterol. 2011; 106: 601-616
        • Kornbluth A.
        • Sachar D.B.
        Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee.
        Am J Gastroenterol. 2010; 105: 501-523
        • Gross V.
        Aminosalicylates. Dig Dis. 2012; 30: 92-99
        • Tursi A.
        • Joseph R.E.
        • Streck P.
        Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.
        Dig Dis Sci. 2011; 56: 3112-3121
        • Strate L.L.
        • Modi R.
        • Cohen E.
        • et al.
        Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
        Am J Gastroenterol. 2012; 107: 1486-1493
        • Tursi A.
        • Brandimarte G.
        • Daffina R.
        Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
        Dig Liver Dis. 2002; 34: 510-515
        • Mulhall A.M.
        • Mahid S.S.
        • Petras R.E.
        • et al.
        Diverticular disease associated with inflammatory bowel disease-like colitis: a systematic review.
        Dis Colon Rectum. 2009; 52: 1072-1079
        • Dughera L.
        • Serra A.M.
        • Battaglia E.
        • et al.
        Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension.
        Minerva Gastroenterol Dietol. 2004; 50: 149-153
        • Unlu C.
        • Daniels L.
        • Vrouenraets B.C.
        • et al.
        Systematic review of medical therapy to prevent recurrent diverticulitis.
        Int J Colorectal Dis. 2012; 27: 1131-1136
        • Tursi A.
        • Brandimarte G.
        • Giorgetti G.M.
        • et al.
        Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.
        Int J Colorectal Dis. 2007; 22: 1103-1108
        • Brandimarte G.
        • Tursi A.
        Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
        Med Sci Monit. 2004; 10: I70-I73
        • Comparato G.
        • Fanigliulo L.
        • Cavallaro L.G.
        • et al.
        Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.
        Dig Dis Sci. 2007; 52: 2934-2941
        • Di Mario F.
        • Aragona G.
        • Leandro G.
        • et al.
        Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
        Dig Dis Sci. 2005; 50: 581-586
        • Tursi A.
        • Brandimarte G.
        • Giorgetti G.
        • et al.
        The clinical picture of uncomplicated versus complicated diverticulitis of the colon.
        Dig Dis Sci. 2008; 53: 2474-2479
        • Trepsi E.
        • Colla C.
        • Panizza P.
        • et al.
        [Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results].
        Minerva Gastroenterol Dietol. 1999; 45: 245-252
        • Tursi A.
        • Brandimarte G.
        • Giorgetti G.M.
        • et al.
        Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon.
        Dig Dis Sci. 2007; 52: 671-674
        • Roberts P.
        • Abel M.
        • Rosen L.
        • et al.
        Practice parameters for sigmoid diverticulitis. The Standards Task Force American Society of Colon and Rectal Surgeons.
        Dis Colon Rectum. 1995; 38: 125-132
        • Frattini J.
        • Longo W.E.
        Diagnosis and treatment of chronic and recurrent diverticulitis.
        J Clin Gastroenterol. 2006; 40: S145-S149
        • Humes D.
        • Simpson J.
        • Spiller R.C.
        Colonic diverticular disease.
        Clin Evid (Online). 2007 Aug 15; 2007 (pii: 0405)
        • Kim T.J.
        • Lee I.K.
        • Park J.K.
        • et al.
        Is conservative treatment with antibiotics the correct strategy for management of right colonic diverticulitis?: a prospective study.
        J Korean Soc Coloproctol. 2011; 27: 188-193
        • Unlu C.
        • Daniels L.
        • Vrouenraets B.C.
        • et al.
        A systematic review of high-fibre dietary therapy in diverticular disease.
        Int J Colorectal Dis. 2012; 27: 419-427
        • Ornstein M.H.
        • Littlewood E.R.
        • Baird I.M.
        • et al.
        Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial.
        Br Med J (Clin Res Ed). 1981; 282: 1353-1356
        • Binda G.A.
        • Arezzo A.
        • Serventi A.
        • et al.
        Multicentre observational study of the natural history of left-sided acute diverticulitis.
        Br J Surg. 2012; 99: 276-285
        • Parente F.
        • Bargiggia S.
        • Prada A.
        • et al.
        Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration.
        Int J Colorectal Dis. 2013; 28: 1423-1431
        • Stollman N.
        • Magowan S.
        • Shanahan F.
        • et al.
        A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.
        J Clin Gastroenterol. 2013; 47: 621-629
        • Strate L.L.
        • Liu Y.L.
        • Aldoori W.H.
        • et al.
        Obesity increases the risks of diverticulitis and diverticular bleeding.
        Gastroenterology. 2009; 136: 115-122
        • Petruzziello L.
        • Iacopini F.
        • Bulajic M.
        • et al.
        Review article: uncomplicated diverticular disease of the colon.
        Aliment Pharmacol Ther. 2006; 23: 1379-1391